Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Matthias Giese

Matthias Giese

CEO & Founder
Institute for Molecular Vaccines


Matthias Giese has studied Molecular Biology and Biochemistry at the Saarland University/Germany. He got a first PhD in Tumor Immunology in the German Cancer Research Center/ Heidelberg. After his PostDoc, Matthias Giese joined the pharmaceutical industry. His team in Vienna/ Austria started the first European multicenter clinical trial with a personalized genetic engineered anti-melanoma vaccine. Also animal health was interested in his expertise in modern vaccine technologies and so he changed the company and headed from now on a global portfolio on innovative vaccine approaches for the next years. His sabbatical leave from the industry was a return back to his academic roots. At Leipzig University/ Germany Matthias Giese got a major PhD (venia legendi) in Molecular Virology. He developed a therapeutical DNA vaccine against a chronic viral infection. This vaccine was able to eliminate the virus and to cure the patient. Currently he is working again for the human pharmaceutical industry as independent consultant (IMV Heidelberg) and additionally he teaches graduate students as associate professor. His focus is on neoantigenes, therapeutical vaccines, and the interaction with immune checkpoint modifiers as combination therapy. Matthias Giese is author of the textbook “Introduction to Molecular Vaccinology“ and other specialized books on modern vaccines. He is an enthusiastic mountain marathon runner.

Research Interest

Therapeutical vaccines, cancer vaccines, neoantigens, novel adjuvants, chronic infections,neurological disorders, modulation of checkpoint inhibitors, signal cascades and immune responses.